TROMS0, Norway--(BUSINESS WIRE)--The Scandinavian-based drug development company Lytix Biopharma today announced it has successfully completed a private placement of NOK50 million. The placement which was heavily oversubscribed by Norwegian institutional and private investors will be used to fund the two areas of the company’s business – antimicrobials and cancer therapeutics. Lytix specialises in micro-sized synthetic peptides offering rapid and selective cell lysis and a follow-on vaccination effect.
